// App-Quantinova.ai

: Randomized controlled trial of abituzumab in systemic sclerosis-associated interstitial lung disease

Researchers

Presenter

  • Dinesh Khanna

Principal Investigators

  • Donald Tashkin

  • Athol Wells

  • Jonathan Goldin

  • Martin Lubell

  • Steven Wax

  • Doris Damian

  • Christopher Denton

Medical Centers

  • University of Michigan - Ann Arbor - United States of America

  • UCLA, Los Angelos, United States of America

  • The Royal Marsden Hospital, London, United Kingdom

  • EMD Serono Inc, Billerica, United States of America

  • UCL Medical School, Royal Free Hospital, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Mycophenolic acid

  • Abituzumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT02745145

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved